Dabibrook 110 mg (Dabigatran)

Dabibrook 110 mg contains Dabigatran, a direct oral anticoagulant (DOAC) used to prevent and treat harmful blood clots and to lower the risk of stroke in patients with non-valvular atrial fibrillation. It works by directly inhibiting thrombin, an essential enzyme in the clotting process. This makes it highly effective for preventing conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE).

The medication is taken orally, typically twice daily, and offers the advantage of not requiring frequent blood monitoring, unlike traditional anticoagulants like warfarin. Dabibrook 110 mg is particularly suited for patients undergoing hip or knee replacement surgery and those with a history of clotting disorders. Common side effects may include gastrointestinal discomfort, bleeding, or nausea. Patients should follow their doctor’s dosage instructions closely and inform healthcare providers of all current medications to avoid interactions. This treatment significantly reduces the risk of stroke and embolic events, improving long-term cardiovascular outcomes.